GlassScriptPhysician profile
Steven P Herman
NPI 1447214903
$2,298.53
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $354 · 2020: $549 · 2021: $379 · 2022: $469 · 2023: $548.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $548.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $547.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $597.39 | 2019-2023 | Farxiga, Fasenra |
| Novo Nordisk INC | $358.06 | 2019-2023 | Rybelsus, Ozempic |
| Lilly USA, LLC | $323.25 | 2019-2023 | Mounjaro, Emgality, Jardiance |
| Glaxosmithkline, LLC. | $313.73 | 2019-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $106.26 | 2019-2023 | Otezla, Repatha |
| Pfizer INC. | $95.94 | 2020-2023 | |
| Amarin Pharma, INC. | $87.11 | 2019-2022 | |
| Daiichi Sankyo INC. | $67.07 | 2021-2022 | |
| Optinose US, INC. | $59.35 | 2020-2022 | |
| Abbvie INC. | $52.62 | 2019-2023 | |
| Kowa Pharmaceuticals America, INC. | $48.38 | 2021-2022 | |
| Braintree Laboratories, INC. | $43.63 | 2019-2021 | |
| Esperion Therapeutics, INC. | $34.39 | 2022 | |
| Upsher-Smith Laboratories LLC | $27.47 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.04 | 2023 | Gattex |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $22.34 | 2023 | Xarelto |
| Biohaven Pharmaceuticals, INC. | $14.48 | 2021 | |
| Merck Sharp & Dohme LLC | $13.41 | 2022 | |
| Neuronetics, INC. | $10.61 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Herman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.